<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01960361</url>
  </required_header>
  <id_info>
    <org_study_id>ICE_001</org_study_id>
    <nct_id>NCT01960361</nct_id>
  </id_info>
  <brief_title>A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of ICE Implant</brief_title>
  <acronym>ICE</acronym>
  <official_title>A Multi-center Study to Evaluate Bone Loss, Survival Rate and Stability of ICE Implant System Over 24 Months, for Patients With Tooth Loss Requiring up to 4 Implants, in Staged Loading Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alpha - Bio Tec Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alpha - Bio Tec Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current prospective clinical study's aim is to determine ABT's ICE implant survival rate,
      crestal interproximal bone resorption during 24 months post implant insertion and to
      assimilate the drilling sequence during the clinical use of ICE implants.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Survival Rate</measure>
    <time_frame>24 MONTHS</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Implant Clinical Survival</condition>
  <condition>Dental Implant Bone Loss</condition>
  <arm_group>
    <arm_group_label>ICE dental implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects implanted with ICE implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ICE dental implant</intervention_name>
    <description>ICE- Implant Classical Esthetic implant</description>
    <arm_group_label>ICE dental implant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women over the age of 18 years who need implantation of 1-4 implants.

          2. Patients who are able to understand the requirements of the study, and are willing and
             able to comply with its instructions and schedules.

          3. Patients who had provided written informed consent to participate in the study prior
             to any study procedure.

          4. Patients in general good health in the opinion of the principal investigator as
             determined by medical history and oral examination.

        Exclusion Criteria:

          1. Immediate loaded implants.

          2. Treatment with anticoagulant drugs (INR under 1.8) or bisphosphonates.

          3. Treatment with anticonvulsants drugs.

          4. Untreated Periodontal disease and inability of the patient to maintain reasonable oral
             hygiene according to study requirements.

          5. Patients with history of alcohol, narcotics or drug abuse.

          6. Patients under steroid therapy.

          7. Patients receiving radiotherapy, chemotherapy or any other immunosuppressive treatment
             or who have been administered radiotherapy in the last 5 years.

             Patients through at anytime received radiotherapy to the head and neck region will be
             excluded anyway.

          8. Metabolic bone disorders and/or bone augmentation.

          9. Uncontrolled bleeding disorders such as: hemophilia, thrombocytopenia,
             granulocytopenia.

         10. Degenerative diseases.

         11. Osteoradionecrosis.

         12. Renal failure.

         13. Organ transplant recipients.

         14. HIV positive.

         15. Malignant diseases.

         16. Diseases that compromise the immune system.

         17. Unbalanced diabetes mellitus. (HbA1c above 6.5)

         18. Psychotic diseases.

         19. Hypersensitivity to one of the components of the implant in general and titanium in
             particular.

         20. Women who are pregnant or lactating.

         21. Lack of patient cooperation.

         22. Uncontrolled endocrine diseases.

         23. Any systemic condition that is unbalanced and therefore precludes surgical procedures.

         24. Parafunctional habits.- e.g Bruxism.

         25. Temporomandibular joint disease.

         26. Various pathologies of the oral mucosa for example: Benign mucous pemphigoid,
             desquamative ginigivitis, erosive lichen planus ,malignancy of oral cavity, bolus
             erosive diseases of the oral mucosa.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Rishon leZion</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>October 9, 2013</study_first_submitted>
  <study_first_submitted_qc>October 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <last_update_submitted>July 14, 2019</last_update_submitted>
  <last_update_submitted_qc>July 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

